Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

This adaptive clinical trial will include a prospective treatment arm (i.e., Furoscix administered via the Furoscix Infusor) administered outside the hospital that will be compared to a propensity-matched historical control arm of patients admitted to the hospital for ≤ 72 hours (i.e., Treatment As Usual (TAU)) that will be derived from administrative claims data. Eligible patients for the Furoscix arm will be patients with HF and fluid overload who initially present to the emergency department (ED) and who are expected to require parenteral diuresis.

If it is determined by the investigator that the patient requires parenteral diuresis or continued diuresis outside of the ED care setting and meets all study eligibility criteria, he/she may be consented and enrolled into the study.

The treatment comprises a preprogrammed bi-phasic 5-hour drug administration. Subjects will be instructed on the use of the Furoscix Infusor by the investigator and/or study staff in accordance with the instructions for use. The initial dose of the study product may be administered in the ED or at home. Additional doses will be provided to the subject for self-administration or administration by a caregiver in the home setting as directed by the investigator or study staff. The total duration in days and total number of doses of the initial therapy will be determined by the investigator based on an estimated volume of diuresis desired to transition patient back to their oral diuretic maintenance therapy. Subjects will receive scheduled at-home telephone calls from a HF nurse on Days 1 and 7 and one call between Days 14-21. Planned in-clinic visits will be conducted between Day 2-4 and then Day 30. Unscheduled at-home telephone calls by a HF nurse and unscheduled in-clinic visits may be performed if felt clinically indicated by the study team or the clinical provider.

The study period will be up to 30 days after enrollment. All outcomes will be assessed up to 30 days after the initial discharge from the emergency department.

Inclusion criteria

• Age 18-80 years
• NYHA Class II-III HF presenting to the emergency department for worsening HF at baseline
• On background therapy includes those receiving 40-160 mg of oral furosemide equivalents daily (20-80 mg Torsemide or 1-4 mg Bumetanide).
• Signs of extracellular volume expansion, defined as one or more of the following:

• jugular venous distention
• pitting edema (≥1+),
• abdominal distension
• pulmonary congestion on chest x-ray
• pulmonary rales
• After initial emergency department evaluation and treatment (i.e., at the time of the care transition decision*), candidates for parenteral diuresis outside of the hospital, defined as all the following:

• Oxygen saturation ≥ 90% on exertion
• Respiratory Rate < 24 breaths per minute
• Resting Heart Rate < 100 beats per minute
• Systolic Blood Pressure > 100 mmHg
• Adequate environment for at-home administration of Furoscix

Exclusion criteria

• Presence of a complicating condition, other than HF that requires immediate hospitalization or anticipated hospitalization in the next 30 days
• Evidence of acute renal failure as determined at the discretion of the investigator
• Known allergy to the active and inactive ingredients of the study medication or device adhesive
• Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
• Currently participating in another interventional research study
• Women who are pregnant or who could become pregnant and are not willing to use an adequate form of contraception
• Estimated Creatinine Clearance < 30 mL per minute by Cockcroft-Gault equation

CrCl (mL/min) = {(140 - age) x Lean Body Weight (kg)/Serum Creatinine (mg/dL) x 72} (x 0.85 if female)

• If baseline creatinine value is available: an increase of ≥ 0.5 mg/dL in creatinine from baseline
• HF requiring immediate hospitalization